SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Aquinox Pharmaceuticals Announces Third Quarter 2018 Financial Results
[November 07, 2018]

Aquinox Pharmaceuticals Announces Third Quarter 2018 Financial Results


VANCOUVER, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the third quarter ending September 30, 2018.

“We ended the third quarter with $86.7 million in cash and cash equivalents and have taken additional steps to reduce expenditures, including further reductions planned in the fourth quarter, to optimize our cash reserves while we evaluate strategic alternatives,” said David Main, President & CEO of Aquinox.

Recent Business Updates

Company Restructuring. In July 2018, Aquinox announced a restructuring plan to reduce operating costs and better align its workforce with the needs of its business. On November 6, 2018, Aquinox’s Board of Directors approved further restructuring to reduce operating costs. Aquinox’s headcount for 2019 will be reduced to eight FTE’s with all R&D activities suspended and no material R&D spending planned while strategic alternatives are being considered.

Summary of Financial Results

Cash Position. Cash and cash equivalents totaled $86.7 million as of September 30, 2018, compared to cash, cash equivalents and short-term investments of $108.1 million as of December 31, 2017. The decrease was primarily the result of expenditures related to the LEADERSHIP 301 clinical trial in IC/BPS and costs associated with restructuring activities, partly off-set by the $25 million payment from Astellas in relation to the exclusive licensing agreement.

R&D Expenses. Research and development expenses for the third quarter of 2018 increased to $10.7 million from $8.5 million in the third quarter of 2017. This increase was primarily driven by costs associated with restructuring activities, including terminating our clinical trials of rosiptor and related contracts. Aquinox expects its research and development expenses to decline over the remainder of 2018 and into 2019 as it completes the closing activities related to the rosiptor clinical trials.

G&A Expenses. General and administrative expenses for the third quarter of 2018 increased to $4.5 million from $3.6 million in the third quarter of 2017. This increase was primarily driven by restructuring costs.

Net Loss. Net loss for the third quarter of 2018 was $15.0 million compared to a net loss of $11.8 million in the third quarter of 2017. This increase was primarily driven by costs associated with restructuring activities, including terminating our clinical trials of rosiptor and related contracts.

About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a pharmaceutical company discovering and developing novel therapeutics for conditions marked by inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.

Cautionary Note on Forward-Looking Statements
Certain of the statements made in this press release are forward looking, including those relating to evaluation of our pipeline and strategic options. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: clinical drug development is a lengthy and expensive process with an uncertain outcome; our ability to identify or acquire additional clinical candidates, our ability to obtain and maintain regulatory approval for any future product candidates and the potential safety, efficacy or clinical utility of or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Aquinox is contained in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 filed with the Securities and Exchange Commission. Aquinox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Info:

Kamran Alam
Vice President, Finance & CFO
Aquinox Pharmaceuticals, Inc.
604.629.9223
ir@aqxpharma.com

 
AQUINOX PHARMACEUTICALS, INC.
 
Condensed consolidated balance sheets
(Unaudited)
(In thousands of U.S. dollars)
 
 
 SEPTEMBER 30,
2018
 DECEMBER 31,
2017
    
Assets   
Cash, cash equivalents and short-term investments$86,731  $108,085 
Other current assets 562   740 
Other long-term assets 521   1,504 
Total assets$87,814  $110,329 
    
Liabilities   
Current liabilities$10,749  $10,956 
Non-current liabilities 343   486 
Total liabilities 11,092   11,442 
Stockholders’ equity 76,722   98,887 
Total liabilities and stockholders' equity$87,814  $110,329 
 




AQUINOX PHARMACEUTICALS, INC.
 
Condensed consolidated statements of operations
(Unaudited)
(In thousands of U.S. dollars, except per share and share amounts)
 
 
 THREE MONTHS ENDED
SEPTEMBER 30,
 NINE MONTHS ENDED
SEPTEMBER 30,
 2018 2017 2018 2017
Revenue$-  $-  $25,000  $- 
Operating expenses       
Research and development 10,713   8,456   39,217   24,708 
General and administrative 4,484   3,614   13,107   9,879 
Total operating expenses 15,197   12,070   52,324   34,587 
Loss from operations (15,197)  (12,070)  (27,324)  (34,587)
Other income, net 204   237   626   672 
Net loss$(14,993) $(11,833) $(26,698) $(33,915)
Net loss per common stock – basic and diluted$(0.64) $(0.50) $(1.14) $(1.45)
        
Basic and diluted weighted average number of common stock outstanding 23,537,368   23,464,785   23,513,489   23,444,181 
                

Aquinox Pharmaceuticals, Inc. Logo



[ Back To TMCnet.com's Homepage ]







Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy